AWY0
Percheron Therapeutics Limited engages in the research and development of novel antisense pharmaceuticals for cancer and rare diseases in Australia. The company's lead asset is ATL1102, an antisense oligonucleotide inhibitor of CD49d, which is in Phase IIb clinical trial for the treatment of Duchenne muscular dystrophy, multiple sclerosis, asthma, and other inflammatory indications. It also devel… Read more
Market Cap & Net Worth: AWY0 (AWY0)
AWY0 (F:AWY0) has a market capitalization of $2.23 Million (€2.17 Million) as of March 19, 2026. Listed on the F stock exchange, this Germany-based company holds position #34895 globally and #4063 in its home market, demonstrating a -33.33% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying AWY0's stock price €0.00 by its total outstanding shares 1087437633 (1.09 Billion).
AWY0 Market Cap History: 2026 to 2026
AWY0's market capitalization history from 2026 to 2026. Data shows growth from $2.23 Million to $2.23 Million (0.00% CAGR).
AWY0 Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how AWY0's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of AWY0 by Market Capitalization
Companies near AWY0 in the global market cap rankings as of March 19, 2026.
Key companies related to AWY0 by market ranking:
- Zoetis Inc (NYSE:ZTS): Ranked #410 globally with a market cap of $53.52 Billion USD.
- Haleon plc (NYSE:HLN): Ranked #434 globally with a market cap of $49.87 Billion USD.
- Takeda Pharmaceutical Co. Ltd. (PINK:TKPHF): Ranked #457 globally with a market cap of $47.47 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #721 globally with a market cap of $28.19 Billion USD ( CN¥206.84 Billion CNY).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #410 | Zoetis Inc | NYSE:ZTS | $53.52 Billion | $121.68 |
| #434 | Haleon plc | NYSE:HLN | $49.87 Billion | $10.60 |
| #457 | Takeda Pharmaceutical Co. Ltd. | PINK:TKPHF | $47.47 Billion | $30.07 |
| #721 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $28.19 Billion | CN¥55.11 |
AWY0 Historical Marketcap From 2026 to 2026
Between 2026 and today, AWY0's market cap moved from $2.23 Million to $ 2.23 Million, with a yearly change of 0.00%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €2.23 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of AWY0 was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $2.23 Million USD |
| MoneyControl | $2.23 Million USD |
| MarketWatch | $2.23 Million USD |
| marketcap.company | $2.23 Million USD |
| Reuters | $2.23 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.